These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Hepatic contrast enhancement at CT: influence of intravenous glucagon in a canine model.
    Author: Warshauer DM, Hiken JN, Molina PL, Hackney SL, Bellinger DA, Lee JK.
    Journal: Radiology; 1995 Nov; 197(2):365-8. PubMed ID: 7480678.
    Abstract:
    PURPOSE: To investigate the effect of glucagon on the timing and degree of hepatic enhancement at computed tomography. MATERIALS AND METHODS: Each of 11 dogs underwent injection of contrast material at two uniphasic rates (0.5 mL/sec and 1.5 mL/sec) with without previous intravenous administration of 0.5 mg of glucagon. Scans were obtained at a single intrahepatic level every 3.5 seconds for 120-160 seconds. Attenuation values in the liver, aorta, portal vein, and inferior vena cava (IVC) were measured. RESULTS: Glucagon administration was associated with greater hepatic enhancement throughout the study: Peak hepatic enhancement was greater at contrast injection rates of 0.5 mL/sec (P = .021) and 1.5 mL/sec (P = .0001). Peak hepatic enhancement also occurred earlier during the glucagon runs. Portal vein enhancement was greater during the glucagon runs at an injection rate of 1.5 mL/sec (P = .032). IVC enhancement was greater during the nonglucagon runs at 0.5 mL/sec (P = .013) and at 1.5 mL/sec (P = .005). CONCLUSION: Intravenous administration of glucagon before contrast material injection produces greater and more rapid hepatic enhancement in a canine model.
    [Abstract] [Full Text] [Related] [New Search]